tradingkey.logo
tradingkey.logo
Search

Grifols SA

GRFS
Add to Watchlist
7.400USD
-0.060-0.80%
Close 06/18, 16:00ETQuotes delayed by 15 min
1.91BMarket Cap
9.54P/E TTM

TradingKey Stock Score of Grifols SA

Currency: USD Updated: 2026-06-18

Key Insights

Grifols SA's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 67 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.73.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Grifols SA's Score

Industry at a Glance

Industry Ranking
67 / 157
Overall Ranking
167 / 4578
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Grifols SA Highlights

StrengthsRisks
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 19.05% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 8.48B.
Undervalued
The company’s latest PE is 9.54, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 148.94M shares, decreasing 5.51% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 63.32M shares of this stock.

Analyst Rating

Based on 8 analysts
Buy
Current Rating
11.730
Target Price
+58.51%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Grifols SA?

The TradingKey Stock Score provides a comprehensive assessment of Grifols SA based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Grifols SA’s performance and outlook.

How do we generate the financial health score of Grifols SA?

To generate the financial health score of Grifols SA, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Grifols SA's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Grifols SA.

How do we generate the company valuation score of Grifols SA?

To generate the company valuation score of Grifols SA, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Grifols SA’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Grifols SA’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Grifols SA.

How do we generate the earnings forecast score of Grifols SA?

To calculate the earnings forecast score of Grifols SA, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Grifols SA’s future.

How do we generate the price momentum score of Grifols SA?

When generating the price momentum score for Grifols SA, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Grifols SA’s prices. A higher score indicates a more stable short-term price trend for Grifols SA.

How do we generate the institutional confidence score of Grifols SA?

To generate the institutional confidence score of Grifols SA, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Grifols SA’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Grifols SA.

How do we generate the risk management score of Grifols SA?

To assess the risk management score of Grifols SA, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Grifols SA’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Grifols SA.
KeyAI